Funds Secured: $75.5 Million in Series A Investment for Revolutionizing Precision Radioligand Therapy (Actithera)
**Actithera Secures $75.5 Million for Radioligand Therapy Development**
Actithera, a biotech company specialising in radioligand therapies (RLTs), has raised an impressive $75.5 million in an oversubscribed Series A financing round. This significant capital injection will propel Actithera's lead Fibroblast Activation Protein (FAP)-targeting RLT into clinical development across multiple indications.
The funding round was co-led by M Ventures, Hadean Ventures, Sofinnova Partners, and 4BIO Capital, with participation from other investors such as Bioqube Ventures, Surveyor Capital, and Arkin Bio Ventures II.
Therese Liechtenstein, Investment Director at 4BIO Capital, expressed her excitement about Actithera's work in aligning pharmacokinetics with therapeutic effect in the RLT space. Roger Franklin, Partner at Hadean Ventures, believes Actithera's molecular design and understanding of tumor biology could transform patient experiences with radioligand therapies.
Actithera's innovative chemistry platform focuses on optimising tumor residence time and improving precision, safety, and efficacy. The platform utilises covalent and irreversible binding to targets to maximise tumor retention and treatment specificity. This approach has been validated through work on FAP, resulting in a promising RLT candidate.
The funds will also support further development of Actithera’s proprietary RLT discovery platform, which is isotope-agnostic, allowing for design flexibility with alpha- or beta-emitting payloads.
Two new board members will join Actithera as a result of the Series A round. Therese Liechtenstein, Investment Director at 4BIO Capital, and Roger Franklin, partner at Hadean Ventures, will bring their strategic insights and industry expertise to Actithera's Board of Directors.
Dr. Andreas Goutopoulos, the founder and CEO of Actithera, with over 25 years of experience in the pharmaceutical and biotech industries, welcomed the new investor group and Board members to Actithera. Hakan Goker, Chairman of Actithera and Managing Director at M Ventures, expressed his excitement to see Actithera evolve from a one-person ideation to a transatlantic company.
Karl Naegler, Partner at Sofinnova Partners, finds Actithera's radioligand therapies to be a meaningful shift in oncology, with the potential to redefine the therapeutic index.
In summary, Actithera plans to utilise the proceeds from its Series A financing round to advance its lead FAP-targeting RLT into clinical development across multiple indications. The company will also continue to develop its proprietary RLT discovery platform, with the aim of translating its novel chemistry into clinical applications.
- The medical-conditions field could potentially see significant advancements with Actithera's lead Fibroblast Activation Protein (FAP)-targeting Radioligand Therapy (RLT) entering clinical development, as per the $75.5 million investment they received.
- Business growth and expansion are on the horizon for Actithera, as their innovative chemistry platform focuses on health-and-wellness improvements by optimizing tumor residence time and improving precision, safety, and efficacy in radioligand therapies.
- As Actithera moves forward with investments in both their lead RLT and proprietary RLT discovery platform, they also invite strategic insights and industry expertise from new board members Therese Liechtenstein (4BIO Capital) and Roger Franklin (Hadean Ventures) to help steer the company's financial (investing) and business operations.
){kind=link}